[
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=6a0f0f9db9527dbc2a6e979367365b72bdd0b4b4204f6f4acc5f3dbe562e396e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733244120,
      "headline": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
      "id": 131778105,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=6a0f0f9db9527dbc2a6e979367365b72bdd0b4b4204f6f4acc5f3dbe562e396e"
    }
  },
  {
    "ts": null,
    "headline": "PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy",
    "summary": "Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.",
    "url": "https://finnhub.io/api/news?id=563feba5ecd2d15a7a21b3a3530263cc163a1d2759dc2533c74339e21fc2d550",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733243220,
      "headline": "PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy",
      "id": 131766732,
      "image": "https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.",
      "url": "https://finnhub.io/api/news?id=563feba5ecd2d15a7a21b3a3530263cc163a1d2759dc2533c74339e21fc2d550"
    }
  },
  {
    "ts": null,
    "headline": "Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?",
    "summary": "Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "url": "https://finnhub.io/api/news?id=79c57a7b0d78d24395f339192ea96fe336620302beb0e24f25ab43f5a1f9db03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733236212,
      "headline": "Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?",
      "id": 131773719,
      "image": "https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
      "url": "https://finnhub.io/api/news?id=79c57a7b0d78d24395f339192ea96fe336620302beb0e24f25ab43f5a1f9db03"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Piper Sandler 36th Annual Healthcare Conference (Transcript)",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) Piper Sandler 36th Annual Healthcare Conference December 3, 2024 11:00 AM ETCompany ParticipantsAndy Dickinson - Chief...",
    "url": "https://finnhub.io/api/news?id=434baac7bda91ed8a6069f2dabd5776c0b0db4f1a4f9555b7c7976eb15d003e3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733233644,
      "headline": "Gilead Sciences, Inc. (GILD) Piper Sandler 36th Annual Healthcare Conference (Transcript)",
      "id": 131756793,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) Piper Sandler 36th Annual Healthcare Conference December 3, 2024 11:00 AM ETCompany ParticipantsAndy Dickinson - Chief...",
      "url": "https://finnhub.io/api/news?id=434baac7bda91ed8a6069f2dabd5776c0b0db4f1a4f9555b7c7976eb15d003e3"
    }
  },
  {
    "ts": null,
    "headline": "Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target",
    "summary": "FOSTER CITY, Calif & MUNICH, December 03, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target.",
    "url": "https://finnhub.io/api/news?id=8622318dc9dc00dde311af4769739bf2dd049055a2714e53cafcecd06bed55b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733227200,
      "headline": "Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target",
      "id": 131773720,
      "image": "https://s.yimg.com/ny/api/res/1.2/kVkHoKyv6yvPSw.yYghWsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/9181cebfe2f773496a200736c43cabb0",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif & MUNICH, December 03, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target.",
      "url": "https://finnhub.io/api/news?id=8622318dc9dc00dde311af4769739bf2dd049055a2714e53cafcecd06bed55b9"
    }
  }
]